Drug Search Results
More Filters [+]

Raseglurant

Alternative Names: raseglurant, adx-10059, adx10059, adx 10059
Latest Update: 2023-12-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MGLUR5 Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Addex Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Raseglurant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastroesophageal Reflux|Esophagitis, Peptic|Bile Reflux|Migraine Disorders|Migraine without Aura|Migraine with Aura

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-005105-18

P2

Completed

Bile Reflux|Gastroesophageal Reflux

2012-12-11

ADX10059-206

P2

Terminated

Migraine Disorders

2010-01-01

2008-005481-30

P2

Terminated

Migraine Disorders

2009-12-14

ADX10059-205

P2

Completed

Esophagitis, Peptic|Gastroesophageal Reflux

2009-12-01

Recent News Events